A retrospective analysis was conducted based on data of the National Health Insurance Fund in Hungary. Overall cancer risk and site-specific cancer risks were analysed in a target trial emulation design when comparing all available antidiabetic therapies to MET and monotherapies and primary combination therapies against each other. The model used in the analysis was corrected for age, gender, co-morbidities, selected cardiovascular medications and inpatient and outpatient visits.
Study Type
OBSERVATIONAL
Enrollment
74,799
Metformin monotherapy
SU monotherapy
DPP-4 inhibitor monotherapy
Pécs
Pécs, Hungary
Overall cancer risk
Time frame: 2016-2022
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
GLP-1 Receptor Agonist monotherapy
SGLT-2 inhibitor monotherapy
Insulin monotherapy
MET + SU combination
MET + DPP-4 inhibitor combination
MET + GLP-1RA combination
MET + SGLT2i combination
MET + insulin combination